Previous 10 |
home / stock / slncf / slncf news
Mallinckrodt (NYSE: MNK ) inks an agreement with British biotech Silence Therapeutics ( OTCPK:SLNCF ) securing exclusive global rights to preclinical-stage SLN500, a C3-targeting RNAi therapeutic candidate plus options to in-license up to two additional complement-targeted assets in Sile...
Silence Therapeutics PLC (SLNCF) Q4 2018 Earnings Conference Call March 11, 2019 08:00 AM ET Company Participants Dr. David Horn Solomon - President and CEO Rob Quinn - Interim CFO Conference Call Participants Miles Dixon - Peel Hunt LLP Presentation Operator Lad...
The following slide deck was published by Silence Therapeutics plc in conjunction with their 2018 Q4 earnings Read more ...
Silence Therapeutics ( OTCPK:SLNCF ): FY GAAP EPS of -26.2p. More news on: Silence Therapeutics plc, Earnings news and commentary, Healthcare stocks news, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Silence Therapeutics Ord Company Name:
SLNCF Stock Symbol:
OTCMKTS Market:
Silence Therapeutics Ord Website:
Divesiran eliminated the need for phlebotomy in all well-controlled patients following infrequent dosing and was well tolerated Data support advancing divesiran into Phase 2 Company to host conference call today at 8:30am Eastern Time Silence Therapeutics plc (“Si...
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming peoples’ lives by silencing diseases through precision engineered medicines, today announced that it will receive a ...
Study demonstrated highly significant and sustained reductions in Lp(a) to week 48 Data support advancing zerlasiran into phase 3 with 300 mg dose Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), an experienced and innovative biotec...